Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 808-818

  Pham, Elizabeth ^a   Birrer, Michael J ^b   Eliasof, Scott ^c   Garmey, Edward G ^c   Lazarus, Douglas ^c   Lee, Christina R ^a   Man, Shan ^a   Matulonis, Ursula A ^d   Peters, Christian G ^c   Xu, Ping ^a   Krasner, Carolyn ^b   Kerbel, Robert S ^a,e  

^a Sunnybrook Health Sciences Centre   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Cerulean Pharma Inc   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CRLX 101; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; UNCLASSIFIED DRUG; CAMPTOTHECIN; CYCLODEXTRIN; IT-101; NANOPARTICLE;

ABDOMINAL PAIN; ADVANCED CANCER; ADVERSE OUTCOME; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INTESTINE OBSTRUCTION; LUNG EMBOLISM; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY METASTASIS; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SEPSIS; SMALL INTESTINE PERFORATION; THROMBOEMBOLISM; TREATMENT RESPONSE; UPREGULATION; VOMITING; ANIMAL; CLINICAL TRIAL; DRUG SCREENING; OVARY TUMOR; PATHOLOGY; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CYCLODEXTRINS; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, SCID; NANOPARTICLES; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923128048     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2810     Document Type: Article

References (47)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438: 967-74.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.
3. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21.
4. Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012;9:378-90.
5. Bergers G, Hanahan D. Modes of resistance to anti-angi ogenic therapy. Nat Rev 2008;8:592-603.
6. Semenza GL. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 2013;32:4057-63.
7. Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, et al. Prognostic significance of hypoxia-inducible factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: An immune histochemical study. BMC Cancer 2008;8:335.
8. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009; 8:1867-77.
9. Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, et al. Potent and sustained inhibition of HIF-1alpha and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 2011;14:245-53.
10. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 2009;8:1596-603.
11. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004;64: 6845-8.
12. Houghton PJ, Cheshire PJ, Hallman JD II, Lutz L, FriedmanHS, Danks MK, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36: 393-403.
13. Khan N, Hou H, Hodge S, Kuppusamy M, Chen EY, Eastman A, et al. Recurrent low-dose chemotherapy to inhibit and oxygenate head and neck tumors. Adv Exp Med Biol 2014;812:105-11.
14. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 2009;106:2353-8.
15. Zeng L, OuG, Itasaka S, HaradaH, Xie X, Shibuya K, et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 2008;99:2327-35.
16. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, et al. Multi histology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res 2011;17:5123-31.
17. Svenson S. What nano medicine in the clinic right now really forms nan oparticles? Wiley Inter discip Rev 2014;6:125-35.
18. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65:36-48.
19. Svenson S, Wolfgang M, Hwang J, Ryan J, Eliasof S. Preclinical to clinical development of the novel camptothecin nano pharmaceutical CRLX101. J Control Release 2011;153:49-55.
20. Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumorbearing mice. Cancer Chemother Pharmacol 2006;57:654-62.
21. Cheng J, Khin KT, Davis ME. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol Pharm 2004;1:183-93.
22. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82.
23. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013;65:71-9.
24. Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CH, Alabi CA, et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci US A 2009;106:11394-9.
25. Gaur S, Wang Y, Kretzner L, Chen L, Yen T, Wu X, et al. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine 2014;10:1477-86.
26. Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J, et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A 2013;110:15127-32.
27. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the anti angiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010;9:996-1006.
28. Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW, et al. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xeno grafts. Int J Cancer 2007;120:2127-34.
29. Young C, Schluep T, Hwang J, Eliasof S. CRLX101 (formerly IT-101)-A novel nanopharmaceutical of camptothecin in clinical development. Curr Bioact Compd 2011;7:8-14.
30. Guerin E, Man S, Xu P, Kerbel RS. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res 2013;73:2743-8.
31. Cruz-Munoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, et al. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis 2014;17:661-73.
32. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006;12:1606-14.
33. Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivela J, Pastorekova S, et al. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 2006;49:594-602.
34. Krasner CN, Birrer MJ, Berlin ST, Horowitz NS, Buss MK, Eliasof S, et al. Phase II clinical trial evaluating CRLX101 in recurrent ovarian, tubal, and peritoneal cancer. J Clin Oncol 32, 2014 (Suppl 5; abstr 5581).
35. Scott DO, Bindra DS, Stella VJ. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Pharm Res 1993;10:1451-7.
36. Schaeppi U, Fleischman RW, Cooney DA. Toxicity of camptothecin (NSC- 100880). Cancer Chemother Rep 1974;5:25-36.
37. Zunino F, Pratesi G. Camptothecins in clinical development. Expert Opin Investig Drugs 2004;13:269-84.
38. Giovanella BC, Harris N, Mendoza J, Cao Z, Liehr J, Stehlin JS. Dependence of anticancer activity of camptothecins on maintaining their lactone function. Ann N Y Acad Sci 2000;922:27-35.
39. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012;7: 383-8.
40. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol 2013;3:259.
41. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013;73: 3347-55.
42. Kerbel RS. Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science 2006;312:1171-5.
43. Poveda AM, Selle F, Hilpert F, Reuss A, Pasic A, Savarese A, et al.Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) - bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): Analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial. Ann Oncol 23, 2012 (suppl 9; abstr LBA26).
44. Keefe SM, Heitjan D, HennesseyM, Robinson J, Mykulowicz K, Marshall A, et al. Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 32, 2014 (suppl 4; abstr 412).
45. Keefe SM, Hennessey M, Gunnarsson O, Mamtani R, Vaughn DJ, Hoffman- Censits JH, et al.Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): results from the planned interim analysis [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego (CA)/Philadelphia (PA): AACR; 2014. (abstr nr CT340).
46. Law TM, Ilson DH, Motzer RJ. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 1994;12:143-5.
47. Hainsworth JD, Shipley DL, Reeves J Jr, Arrowsmith ER, Barnes EK, Waterhouse DM. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: A phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Genitourin Cancer 2013;11:283-9 e1. 818.